RECRUITING

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Conditions

ARB BVMD Autosomal-Dominant Bestrophinopathy Best Vitelliform Macular Dystrophy Bestrophinopathy OPGx-BEST1

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are: Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB. A second question it aims to answer is identification of the most appropriate dose strength of OPGx-BEST1 for clinical development. Evaluate the efficacy of single injection of OPGx-BEST1 in one eye for 5 years post-injection. What medical problems do participants have when taking drug OPGx-BEST1?

Official Title

A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)

Quick Facts

Study Start:2025-09

Study Completion:2030-08

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07185256

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Provide informed consent to study assessments. 2. Able and willing to comply with all study assessments for the duration of the study. 3. ≥18 years old. 4. ETDRS BCVA measured with standard testing distances: 1. For the sentinel participant in each cohort, ≤20 letters (Snellen equivalent of 20/200 \[1.30 logMAR\] or worse) 2. For subsequent participants in the same cohort, 65 to 20 letters inclusive (Snellen equivalent of 20/50 \[0.40 logMAR\] to 20/200 \[1.30 logMAR\]). 5. Genetic confirmation on chromosome 11q12-q13.1 of BVMD or ARB with a BEST1 genetic test or IRD panel test including a BEST1 variant test, by a Clinical Laboratory Improvement Amendments (CLIA) or European certified laboratory. If available test result is more than 15 years old, confirmation testing will be performed at Visit 1, with results needed by Visit 3. 6. Confirmation of one disease-causing (pathogenic or likely pathogenic, autosomal-dominant) variant in the BEST1 gene for BVMD, as listed in the IB, or two variants for ARB per American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) variant interpretation. 7. BVMD: Clinical phenotype and diagnosis consistent with advanced BVMD with active subretinal fluid or vitelliform material. 8. ARB: Clinical phenotype and diagnosis consistent with ARB.	1. Women of childbearing potential (WOCBP) who are pregnant, lactating, and/or unwilling to use effective contraception from Screening through 1 year after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines. 2. Men who are unwilling to use adequate contraception from Screening through 180 days after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines. 3. Have a pre-existing eye condition or complicating systemic disease that could preclude the planned surgery (e.g., individuals who are immunocompromised, on continuous systemic immunosuppressive treatment or anticipate a need to initiate it for non-study reasons, or unable to take the concomitant immuno-suppressive regimen necessary for IMP administration). 4. Have a history of disease that may preclude the individual from study participation (e.g., other bestrophinopathy, such as AOFVD or ADVIRC) or that may interfere with or preclude outcome measure testing as described in the protocol. 5. Have previously received gene therapy of any kind. 6. Presence of active choroidal neovascularization (CNV) that, in the opinion of the Investigator, affects vision or may require treatment. 7. Presence of subretinal fibrosis that may significantly limit improvement in visual acuity. 8. Have an epiretinal membrane that may require surgical intervention. 9. Have undergone tube surgery for glaucoma at any time or have glaucoma that has been unstable within the past 4 years. Note: Prior incisional surgery (e.g., trabeculectomy and iridotomy) is not exclusionary. 10. Had intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery. 11. Have used any investigational drug or device within 90 days prior to planned IMP administration or plan to participate in another drug or device study during the same period as the current study. 12. Have received a vaccination within 6 weeks prior to planned IMP administration or plan to be vaccinated within 6 months after IMP administration. 13. Have received anticoagulant therapy within 2 weeks prior to planned IMP administration. 14. Have active macular neovascularization as determined by OCT-A. 15. Are incapable of performing visual function testing for reasons other than poor vision. 16. Have any contraindication to the concomitant steroid regiment proscribed in the protocol. 17. Have any other condition (ocular, medical, or psychological) that would not allow the individual to complete follow-up examinations during the study and/or, in the opinion of the Investigator, makes it hazardous or unsuitable for the individual to participate in the study. 18. Have a known history of hypersensitivity to constituents or excipients in the pharmaceutical formulation of the IMP. 19. Have a known infection of human immunodeficiency virus (HIV), hepatitis B or C virus, or herpes simplex virus. 20. Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.

Inclusion Criteria

Exclusion Criteria

1. Provide informed consent to study assessments.
2. Able and willing to comply with all study assessments for the duration of the study.
3. ≥18 years old.
4. ETDRS BCVA measured with standard testing distances:
1. For the sentinel participant in each cohort, ≤20 letters (Snellen equivalent of 20/200 \[1.30 logMAR\] or worse)
2. For subsequent participants in the same cohort, 65 to 20 letters inclusive (Snellen equivalent of 20/50 \[0.40 logMAR\] to 20/200 \[1.30 logMAR\]).
5. Genetic confirmation on chromosome 11q12-q13.1 of BVMD or ARB with a BEST1 genetic test or IRD panel test including a BEST1 variant test, by a Clinical Laboratory Improvement Amendments (CLIA) or European certified laboratory. If available test result is more than 15 years old, confirmation testing will be performed at Visit 1, with results needed by Visit 3.
6. Confirmation of one disease-causing (pathogenic or likely pathogenic, autosomal-dominant) variant in the BEST1 gene for BVMD, as listed in the IB, or two variants for ARB per American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) variant interpretation.
7. BVMD: Clinical phenotype and diagnosis consistent with advanced BVMD with active subretinal fluid or vitelliform material.
8. ARB: Clinical phenotype and diagnosis consistent with ARB.

1. Women of childbearing potential (WOCBP) who are pregnant, lactating, and/or unwilling to use effective contraception from Screening through 1 year after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines.
2. Men who are unwilling to use adequate contraception from Screening through 180 days after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines.
3. Have a pre-existing eye condition or complicating systemic disease that could preclude the planned surgery (e.g., individuals who are immunocompromised, on continuous systemic immunosuppressive treatment or anticipate a need to initiate it for non-study reasons, or unable to take the concomitant immuno-suppressive regimen necessary for IMP administration).
4. Have a history of disease that may preclude the individual from study participation (e.g., other bestrophinopathy, such as AOFVD or ADVIRC) or that may interfere with or preclude outcome measure testing as described in the protocol.
5. Have previously received gene therapy of any kind.
6. Presence of active choroidal neovascularization (CNV) that, in the opinion of the Investigator, affects vision or may require treatment.
7. Presence of subretinal fibrosis that may significantly limit improvement in visual acuity.
8. Have an epiretinal membrane that may require surgical intervention.
9. Have undergone tube surgery for glaucoma at any time or have glaucoma that has been unstable within the past 4 years. Note: Prior incisional surgery (e.g., trabeculectomy and iridotomy) is not exclusionary.
10. Had intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery.
11. Have used any investigational drug or device within 90 days prior to planned IMP administration or plan to participate in another drug or device study during the same period as the current study.
12. Have received a vaccination within 6 weeks prior to planned IMP administration or plan to be vaccinated within 6 months after IMP administration.
13. Have received anticoagulant therapy within 2 weeks prior to planned IMP administration.
14. Have active macular neovascularization as determined by OCT-A.
15. Are incapable of performing visual function testing for reasons other than poor vision.
16. Have any contraindication to the concomitant steroid regiment proscribed in the protocol.
17. Have any other condition (ocular, medical, or psychological) that would not allow the individual to complete follow-up examinations during the study and/or, in the opinion of the Investigator, makes it hazardous or unsuitable for the individual to participate in the study.
18. Have a known history of hypersensitivity to constituents or excipients in the pharmaceutical formulation of the IMP.
19. Have a known infection of human immunodeficiency virus (HIV), hepatitis B or C virus, or herpes simplex virus.
20. Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.

Contacts and Locations

Study Contact

Mark Pennesi, M.D., Ph.D

CONTACT

214-363-3911

Pennesi@retinafoundation.org

Study Locations (Sites)

Retina Foundation of the Southwest

Dallas, Texas, 75231

United States

Collaborators and Investigators

Sponsor: Opus Genetics, Inc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09

Study Completion Date2030-08

Study Record Updates

Study Start Date2025-09

Study Completion Date2030-08

Terms related to this study

Keywords Provided by Researchers

Bestrophinopathy
BVMD
ARB
OPGx-BEST1
Best vitelliform macular dystrophy
Autosomal-Dominant Bestrophinopathy

Additional Relevant MeSH Terms

ARB
BVMD
Autosomal-Dominant Bestrophinopathy
Best Vitelliform Macular Dystrophy